A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
about
Induced Stem Cells as a Novel Multiple Sclerosis TherapyInjectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis.Glatiramer acetate in multiple sclerosis.Glatiramer acetate for multiple sclerosis: a comprehensive review of mechanisms and clinical efficacy.Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence.Comparative effectiveness of interferons in relapsing-remitting multiple sclerosis: a meta-analysis of real-world studies.Immunomodulatory treatment of multiple sclerosis in denmark: a prospective nationwide survey.A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.A retrospective, observational study comparing the four available immunomodulatory treatments for relapsing-remitting multiple sclerosis.Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone).Sample size estimates for determining treatment effects in high-risk patients with early relapsing-remitting multiple sclerosis.Beneficial effect of glatiramer acetate (Copaxone) on immune modulation of experimental hepatic fibrosis.Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients.
P2860
Q28081780-A4078304-6727-4D4B-8DA3-AF2BBB13B8B5Q35557398-C438AA8F-CDEE-464A-AE59-856C8E664343Q36198583-EFB9731C-951A-4632-9A16-88752EC292DDQ37610176-E427CBC5-5E15-4C5E-BE0D-9F5293D62702Q37976344-04B4B1DE-0235-429F-83CA-2ACA3010CECAQ39061969-0B4C7F2D-2E18-4F83-BAFC-2ECB9427F8AEQ42687809-1326C529-6A3C-445B-84E1-027CB92EE24EQ43857255-2BDCA6C8-CDAE-4EAF-921A-633D5E3DF79BQ44670939-19CF676B-6CE3-4BC9-BDF0-EB4052F4E344Q46482938-C1BD5D00-B3E5-48BF-9925-2298B38974D0Q47450338-755BE19F-E9AD-44AC-B314-A53092000F2CQ50718386-77405614-3CB4-4D0D-A27A-F7CFB57CC611Q51491050-32C21054-0DF0-4786-B4A6-9B6A14AA16F2
P2860
A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
A prospective, open-label trea ...... -remitting multiple sclerosis.
@en
A prospective, open-label trea ...... -remitting multiple sclerosis.
@nl
type
label
A prospective, open-label trea ...... -remitting multiple sclerosis.
@en
A prospective, open-label trea ...... -remitting multiple sclerosis.
@nl
prefLabel
A prospective, open-label trea ...... -remitting multiple sclerosis.
@en
A prospective, open-label trea ...... -remitting multiple sclerosis.
@nl
P2093
P2860
P1476
A prospective, open-label trea ...... -remitting multiple sclerosis.
@en
P2093
P2860
P304
P356
10.1046/J.1468-1331.2001.00189.X
P577
2001-03-01T00:00:00Z